Incidence of pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment

摘要

Sir - After pazopanib's approval for the treatment of soft tissue sarcomas, pneumothorax was reported as an unexpected adverse event linked to pazopanib treatment. Pneumothorax was rarely reported in the pre-approval clinical trials of pazopanib [1], so the incidence of pneumothorax during pazopanib treatment has not yet been established.